- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tapentadol PR improves pain, QoL in osteoarthritis patients
Germany: Tapentadol prolonged-release (PR) is a useful strong analgesic to improve pain intensity, physical functioning and quality of life in elderly osteoarthritis (OA) patients, according to a recent study published in the journal Pain Management.
Osteoarthritis is a painful and debilitating disease of joints. It affects the entire joint, involving the cartilage, joint lining, ligaments, and bone. Pain and disability is the hallmark of osteoarthritis and it has become one of the leading cause of disability in older adults, affecting 9.6% of elderly men and 18% of elderly women. OA pain leads to severe impairments in physical functioning and quality of life.
Christian Elling, Grünenthal GmbH, Aachen, Germany, and colleagues extracted data of patients with severe chronic knee and/or hip OA pain from the database of a prospective, noninterventional trial to assess the benefits of tapentadol prolonged-release in elderly patients (>65 years of age; n = 1162) compared with younger patients (≤65 years of age; n = 498).
Pain was assessed by the Numerical Rating Scale (scores 0-10, with 10 being worst pain). QoL was assessed by the Short Form-12 (scores 0-100, with 100 being least disabled).
Key findings of the study include:
- 53.5% of the elderly at baseline had been in pain for >2 years vs 49% of nonelderly.
- After 3 months of treatment with tapentadol PR:
- Pain was reduced by 3.8 points in elderly (52.1%) and 4 points in nonelderly patients (54.8%).
- QoL (physical component) rose by 11.8 points in elderly and 12.3 points in nonelderly patients.
- QoL (mental component) rose by 12.4 points in elderly and 13.5 points in nonelderly patients.
- AEs occurred in 2.4% of elderly and 3.4% of nonelderly patients.
"Tapentadol PR is tied to reduced pain and improved QoL with a low rate of adverse events (AEs) in elderly patients with osteoarthritis (OA)," concluded the authors.
The study, "Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life," is published in the journal Pain Management.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751